Literature DB >> 6992934

Insulin-induced lipoatrophy: evidence for an immune pathogenesis.

W G Reeves, B R Allen, R B Tattersall.   

Abstract

Skin biopsy samples from 14 diabetic patients with lipoatrophy at injection sites and from five insulin-treated diabetic patients without such lipoatrophy (controls) were examined by immunofluorescence for the deposition of immunological components. Also sera from 13 of the patients with lipoatrophy and from all of the controls were assayed for insulin-binding capacity. Biopsy samples from the edge of lipoatrophic areas (eight cases) invariably showed abnormal deposition of immunological components in dermal vessel walls, whereas no such deposition was seen in the control samples. Mean serum insulin-binding capacity was 33.1 microgram/l in the patients with lipoatrophy compared with only 4.6 microgram/l in the controls. These findings suggest that insulin-induced lipoatrophy results from the local formation of immune complexes, complement fixation, and release of inflammatory mediators from the cellular infiltrate.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6992934      PMCID: PMC1601688          DOI: 10.1136/bmj.280.6230.1500

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  10 in total

1.  [Diabetes mellitus and the adipose tissue].

Authors:  A E RENOLD; A I WINEGRAD; D B MARTIN
Journal:  Helv Med Acta       Date:  1957-10

2.  Lipodystrophy following insulin injections.

Authors:  R G PALEY
Journal:  Metabolism       Date:  1953-05       Impact factor: 8.694

3.  Action of insulin on deposition of glycogen and storage of fat in adipose tissue.

Authors:  A E RENOLD; A MARBLE; D W FAWCETT
Journal:  Endocrinology       Date:  1950-01       Impact factor: 4.736

4.  Congenital generalized lipodystrophy with insulin-resistant diabetes.

Authors:  S Kodama; M Kasuga; A Seki; M Ninomiya; T Sakurai; Y Morishita; M Matsuo; T Matsuo
Journal:  Eur J Pediatr       Date:  1978-01-17       Impact factor: 3.183

5.  Restoration of growth by human growth hormone (Roos) in hypopituitary dwarfs immunized by other human growth hormone preparations: clinical and immunological studies.

Authors:  L E Underwood; S J Voina; J J Van Wyk
Journal:  J Clin Endocrinol Metab       Date:  1974-02       Impact factor: 5.958

6.  Variations in the incidence of lipodystrophy using different insulins.

Authors:  D Watson; R Vines
Journal:  Med J Aust       Date:  1973-02-03       Impact factor: 7.738

7.  Very pure porcine insulin in clinical practice.

Authors:  A D Wright; C H Walsh; M G Fitzgerald; J M Malins
Journal:  Br Med J       Date:  1979-01-06

8.  Use of dexamethasone in treatment of insulin lipoatrophy.

Authors:  O Kumar; L Miller; S Mehtalia
Journal:  Diabetes       Date:  1977-04       Impact factor: 9.461

Review 9.  Insulin preparations and the clinical use of insulin.

Authors:  J E Poulsen; T Deckert
Journal:  Acta Med Scand Suppl       Date:  1976

10.  Partial lipodystrophy and insulin-resistant diabetes.

Authors:  P Crome; H Keen
Journal:  Diabete Metab       Date:  1978-06
  10 in total
  28 in total

Review 1.  Lipoatrophic diabetes and other related syndromes.

Authors:  Elif Arioglu Oral
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

Review 2.  The skin in diabetes mellitus.

Authors:  M J Goodfield; L G Millard
Journal:  Diabetologia       Date:  1988-08       Impact factor: 10.122

3.  Human insulin.

Authors:  J Pickup
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-18

4.  Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins.

Authors:  P G McNally; N I Jowett; J J Kurinczuk; R W Peck; J R Hearnshaw
Journal:  Postgrad Med J       Date:  1988-11       Impact factor: 2.401

5.  Paradoxical lipodystrophic changes due to conventional bovine and highly purified porcine/bovine insulins.

Authors:  I W Campbell; C Duncan; A R Anani
Journal:  Postgrad Med J       Date:  1984-06       Impact factor: 2.401

Review 6.  Insulin antibody determination: theoretical and practical considerations.

Authors:  W G Reeves
Journal:  Diabetologia       Date:  1983-06       Impact factor: 10.122

7.  The influence of insulin antibody levels on the plasma profiles and action of subcutaneously injected human and bovine short acting insulins.

Authors:  A J Francis; I Hanning; K G Alberti
Journal:  Diabetologia       Date:  1985-06       Impact factor: 10.122

8.  Controlled study comparing treatment with monocomponent insulin and conventional insulin in patients with lipoatrophy.

Authors:  A Czyzyk; H Rogala; J Lawecki
Journal:  Acta Diabetol Lat       Date:  1989 Jan-Mar

Review 9.  Adverse effects of exogenous insulin. Clinical features, management and prevention.

Authors:  A W Patrick; G Williams
Journal:  Drug Saf       Date:  1993-06       Impact factor: 5.606

10.  Immunogenicity of highly purified bovine insulin: a comparison with conventional bovine and highly purified human insulins.

Authors:  R M Wilson; C A Douglas; R B Tattersall; W G Reeves
Journal:  Diabetologia       Date:  1985-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.